Trillium begins dosing in Phase I trial of TTI-621 for solid tumours and mycosis fungoides
Clinical stage immuno-oncology company Trillium Therapeutics has begun dosing in its second Phase I clinical trial of TTI-621 (SIRPaFc) in patients with relapsed or refractory percutaneously accessible solid tumours and mycosis fungoides.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Clinical Trials | Cutaneous T cell lymphoma | Mycosis Fungoides | Pharmaceuticals